Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR9COG)

Drug Name

STX-100 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-V/beta-6 (ITGAV/B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PLN-74809	DMQDN46	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[3]
CWHM-12	DM8YUJT	Hepatic fibrosis	DB93.0	Preclinical	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01371305) STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
2	Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896.
3	Dual inhibition of alpha(v)beta(6) and alpha(v)beta(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265.
4	Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24.